AASM Sleep Medicine Disruptors: Innovation Driving the Future of Sleep Care

AASM Sleep Medicine Disruptors: Innovation Driving the Future of Sleep Care

The field of sleep medicine is rapidly evolving, and innovation is at the center of that transformation. The American Academy of Sleep Medicine (AASM) continues to spotlight this progress through its Sleep Medicine Disruptors Innovation Award—recognizing technologies that are reshaping how sleep disorders are diagnosed and managed.

Read more about the award winners here:
https://aasm.org/aasm-sleep-medicine-disruptors-innovation-award-winners/

As highlighted by AASM, the next generation of sleep solutions is focused on improving access, increasing diagnostic accuracy, and reducing the burden on both patients and providers.

For sleep clinics and program directors, this shift reflects a growing need for tools that can:

  • Expand diagnostic capacity without adding staff
  • Reduce reliance on a single testing pathway
  • Improve confidence in diagnosing complex, multi-disorder patients

The traditional gap between in-lab polysomnography (PSG) and home sleep testing continues to create bottlenecks in care delivery. New technologies are emerging to bridge that gap—bringing clinical-grade insights into more scalable, patient-friendly environments.

Dormotech is part of this movement, focused on enabling more flexible, comprehensive sleep diagnostics that align with how modern sleep programs need to operate. As the industry evolves, the emphasis is no longer just on testing—but on delivering the right test for the right patient at the right time, without compromising clinical integrity.


DormoVision X™ delivers automated, AI-supported analysis with multi-night data capture, enabling more accurate and confident clinical decisions. Designed to integrate into existing workflows, the platform helps sleep programs expand diagnostic capacity without increasing staff burden—supporting higher-quality care at scale.

If your organization is evaluating how to expand diagnostic reach without defaulting every patient to either traditional in-lab PSG or limited-channel home testing alone, Dormotech is worth a closer look.

Contact Dormotech

For further information about Dormotech, please contact:
Abed Nassir, CEO (abed@dormotech.com)
Kyle Hunter, CCO (kyle@dormotech.com)

Keep up to date with our latest news and announcements!

Sign up with Dormotech to stay up to date on upcoming events, releases, and new research.